Spectral AI, Inc.
MDAI Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2021βFY2025
What Spectral AI, Inc. does
No business description yet.
- Legal name
- Spectral AI, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 25, 2026
- Accession Β· CIK
- 0001213900-26-033808
0001833498
Revenue and margins
Spectral AI, Inc. had $19.7M of revenue in fiscal 2025, down 33.6% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β in fiscal 2025, β of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Spectral AI, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 47.9%.
Balance sheet
Cash, debt and the ratios that show how comfortably Spectral AI, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.8M | $14.2M | $4.8M | $5.2M | $15.4M |
| Debt incl. finance leases | β | β | β | $2.8M | $9.3M |
| Interest coverage | β | β | β | β | β9.7x |
| Current ratio | 0.4x | 2.8x | 0.8x | 0.6x | 0.9x |
| Quick ratio | 0.4x | 2.8x | 0.8x | 0.5x | 0.9x |
| Total assets | $254M | $18.7M | $10.7M | $12.1M | $21.4M |
| Total liabilities | $21.9M | $6.7M | $12.4M | $19.3M | $27.1M |
| Shareholders' equity | $13.8M | $12.0M | β$2.1M | β$7.3M | β$5.7M |
| Net debt (β = net cash) | β | β | β | β$2.4M | β$6.2M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β |
| F-score | β / 3 | β / 6 | 3 / 8 | 4 / 8 | 3 / 9 |
| Accruals ratio | β0.5% | β1.3% | β51.8% | β52.3% | 14.0% |
| Altman Z'' | 0.25 | 2.81 | β19.87 | β21.13 | β11.78 |
5 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.3M | $25.4M | $18.1M | $29.6M | $19.7M |
| Net interest income | $1.3M | $12.9M | β | β | β |
| Gross profit | β | $10.8M | $7.9M | $13.3M | $8.9M |
| Research and development | β | $16.5M | $15.1M | β | β |
| Operating income | β$3.4M | β$2.6M | β$13.0M | β$6.6M | β$8.6M |
| Interest expense | β | β | β | β$0.0M | $0.9M |
| Pretax income | β$2.1M | β$2.8M | β$20.8M | β$15.0M | β$7.6M |
| Income tax | $0.0M | $0.1M | $0.0M | $0.1M | $0.0M |
| Net income | β$2.1M | β$2.9M | β$20.9M | β$15.2M | β$7.6M |
| Diluted EPS | β | β$0.22 | β$1.48 | β$0.85 | β$0.29 |
| Diluted shares | β | 0.01B | 0.01B | 0.02B | 0.03B |
| Cash flow | |||||
| Cash from operations | β$0.8M | β$1.2M | β$13.2M | β$9.2M | β$9.9M |
| Depreciation and amortization | β | $0.0M | $0.0M | $0.0M | $0.1M |
| Stock-based compensation | β | $1.2M | $1.2M | $1.0M | $1.1M |
| Share buybacks | $0.0M | $251M | β | β | β |
| Dividends and buybacks | $0.0M | $251M | β | β | β |
| Balance sheet | |||||
| Cash and short-term investments | $0.8M | $14.2M | $4.8M | $5.2M | $15.4M |
| Total debt | β | β | β | $2.8M | $9.3M |
| Current assets | $1.1M | $17.7M | $9.9M | $10.1M | $19.5M |
| Current liabilities | $2.9M | $6.4M | $12.4M | $17.6M | $20.6M |
| Inventory | β | β | $0.2M | $0.4M | $0.8M |
| Property and equipment, net | β | $0.0M | $0.0M | $0.0M | $0.3M |
| Total assets | $254M | $18.7M | $10.7M | $12.1M | $21.4M |
| Total liabilities | $21.9M | $6.7M | $12.4M | $19.3M | $27.1M |
| Preferred stock | $0.0M | $0.0M | β | β | β |
| Shareholders' equity | $13.8M | $12.0M | β$2.1M | β$7.3M | β$5.7M |
| Margins | |||||
| Gross margin | β | 42.7% | 43.6% | 44.9% | 45.4% |
| Operating margin | β268.9% | β10.4% | β71.9% | β22.3% | β43.8% |
| EBITDA margin | β | β10.4% | β71.9% | β22.2% | β43.4% |
| Net margin | β168.9% | β11.5% | β115.5% | β51.2% | β38.5% |
| Net interest share of revenue | 100.0% | 50.9% | β | β | β |
| Returns | |||||
| Return on capital employed | β1.4% | β21.4% | 759.7% | 118.6% | β1,104.4% |
| Return on equity | β15.6% | β22.6% | β423.6% | β | β |
| Return on assets | β0.8% | β2.1% | β141.8% | β133.0% | β45.2% |
| Return on tangible equity | β15.6% | β24.3% | β | β | β |
| Growth | |||||
| Revenue growth | β | 1,893.9% | β28.8% | 63.8% | β33.6% |
| Share count change | β | β | 7.2% | 27.3% | 47.9% |
| Financial health | |||||
| Interest coverage | β | β | β | β | β9.7x |
| Current ratio | 0.4x | 2.8x | 0.8x | 0.6x | 0.9x |
| Quick ratio | 0.4x | 2.8x | 0.8x | 0.5x | 0.9x |
| Capital allocation | |||||
| Stock comp / revenue | β | 4.6% | 6.9% | 3.5% | 5.7% |
| Quality scores | |||||
| Piotroski F-score | β | β | 3.0 | 4.0 | 3.0 |
| Altman Z'' | 0.3 | 2.8 | β19.9 | β21.1 | β11.8 |
| Accruals ratio | β0.5% | β1.3% | β51.8% | β52.3% | 14.0% |
Source: SEC EDGAR XBRL filings (CIK 0001833498). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.